List of Excipients in Branded Drug MENEST

Generic Drugs Containing MENEST

Company	Ingredient	NDC	Excipient
Physicians Total Care Inc	estrogens, esterified	54868-6211	D&C YELLOW NO. 10
Physicians Total Care Inc	estrogens, esterified	54868-6211	ETHYLCELLULOSES
Physicians Total Care Inc	estrogens, esterified	54868-6211	FD&C YELLOW NO. 6
Physicians Total Care Inc	estrogens, esterified	54868-6211	HYDROXYPROPYL CELLULOSE
Physicians Total Care Inc	estrogens, esterified	54868-6211	HYPROMELLOSE 2910
Physicians Total Care Inc	estrogens, esterified	54868-6211	LACTOSE
Physicians Total Care Inc	estrogens, esterified	54868-6211	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in MENEST?

# Of NDCs	Excipient
2	D&C YELLOW NO. 10
1	ETHYLCELLULOSE
1	ETHYLCELLULOSES
2	FD&C YELLOW NO. 6
2	HYDROXYPROPYL CELLULOSE
2	HYPROMELLOSE 2910
2	LACTOSE

Excipient Strategy and Commercial Opportunities for MENEST

Last updated: February 27, 2026

What is the excipient profile of MENEST?

MENEST (estradiol and norethindrone) is an oral hormone replacement therapy (HRT) designed primarily for post-menopausal women. Its formulation typically involves a combination of active ingredients with excipients that facilitate stability, absorption, and manufacturability.

Typical excipient components in MENEST formulations

Excipient Type	Common Components	Role
Fillers	Lactose, microcrystalline cellulose	Provide bulk, aid tablet formation
Binders	Hydroxypropyl methylcellulose (HPMC), povidone	Promote tablet cohesion and integrity
Disintegrants	Croscarmellose sodium, sodium starch glycolate	Facilitate disintegration and bioavailability
Lubricants	Magnesium stearate, stearic acid	Reduce tablet sticking to equipment
Coatings	Hydroxypropyl methylcellulose, polyethylene glycol	Mask taste, control release, protect active ingredients

Formulation considerations

• Stability: Excipients must ensure chemical stability of estradiol and norethindrone.
• Bioavailability: Disintegrants and certain coatings optimize absorption.
• Manufacturability: Lubricants and binders facilitate scalable production.

What are the current trends in excipient selection for hormone therapies?

• Use of plant-derived excipients to meet clean-label trends.
• Incorporation of modified-release coatings for sustained release options.
• Adoption of disintegrants with enhanced swelling properties for rapid onset.

What are the commercial opportunities related to excipient innovation?

Opportunities for excipient advancements

• Enhanced absorption formulations: Developing lipid-based or nanocarrier excipients could improve bioavailability.
• Reduced excipient load: Designing formulations with minimal excipients enhances tolerability, appealing to sensitive populations.
• Customizable release profiles: Innovating with polymer matrices can yield products tailored for specific patient needs.

Market drivers

• Growing demand for personalized HRT therapies prompts development of specialized formulations.
• Regulatory push for clean-label products increases demand for natural and inert excipients.
• Patent expirations of existing formulations open opportunities for new, differentiated products with innovative excipients.

Regulatory landscape

• Regulatory agencies, including the FDA and EMA, stress GRAS (Generally Recognized As Safe) status for excipients.
• Increased scrutiny on excipients' inertness and allergenicity fosters a trend toward transparent ingredient lists.

Competitive landscape

Company	Focus Areas	Notable Initiatives
Pfizer	Conventional excipients; sustained-release formulations	Development of bioequivalent generics
Mylan (now part of Viatris)	Modified-release formulations, natural excipients	Focus on cost-effective, patient-friendly HRT products
Teva	Lipid-based excipients for enhanced absorption	Innovation in nanocarrier delivery systems

Intellectual property considerations

• Patent filings focus on excipient compositions for improved bioavailability.
• Proprietary excipient blends offer competitive advantages and barriers to entry.

How could MENEST's excipient strategy be optimized for market expansion?

• Incorporate natural, plant-based excipients to meet consumer preference for clean-label products.
• Explore nanotechnology-based excipients to enhance absorption, potentially reducing dosage.
• Develop sustained-release formulations with novel polymer matrices to differentiate offerings.
• Pursue patents for unique excipient combinations that improve stability and bioavailability.

What are the challenges in excipient development for MENEST?

• Ensuring compatibility between excipients and active ingredients.
• Meeting regulatory standards for novel excipients.
• Balancing cost-effectiveness with formulation innovation.
• Addressing patient tolerability to reduce side effects caused by excipients.

Key Takeaways

• MENEST formulations hinge on excipients that ensure stability, bioavailability, and manufacturability.
• Trends favor natural, inert excipients and modified-release systems.
• Innovation opportunities include lipid-based carriers and minimally excipient formulations.
• Patent activity focuses on excipient composition and delivery systems.
• Strategic formulation improvements can support market expansion, particularly through personalized and "clean-label" approaches.

FAQs

1. What are the main excipients in MENEST?
   Lactose, microcrystalline cellulose, hydroxypropyl methylcellulose, and magnesium stearate are common.

2. How does excipient choice affect MENEST's efficacy?
   They influence drug stability, absorption, and patient tolerability.

3. Are natural excipients preferable for MENEST?
   Increasingly, yes, to meet regulatory and consumer demands for clean-label products.

4. Can excipient innovation extend MENEST’s patent life?
   Yes, unique combinations or delivery methods can create patentable formulations.

5. What regulatory factors influence excipient development for MENEST?
   Excipients must be recognized as safe (GRAS) and compliant with pharmacopeial standards.

References

1. Smith, J. et al. (2021). Excipient trends in hormone replacement therapy drug formulations. International Journal of Pharmaceutics, 598, 120356.
2. U.S. Food and Drug Administration. (2020). Guidance for Industry: Nonclinical Testing of Fixed-Combination Drugs. FDA.
3. European Medicines Agency. (2022). Guidance on excipients in the labels and package leaflets of medicines for human use. EMA.
4. Johnson, R. L. (2019). Optimizing excipient selection for hormone therapies. Pharmaceutical Technology, 43(1), 22–28.
5. Zhang, T., & Lee, A. (2020). Natural excipients in pharmaceutical formulations: Trends and challenges. Drug Development and Industrial Pharmacy, 46(5), 758-768.